Imagine a world where millions of Americans grappling with chronic pain, nausea from chemotherapy, or appetite loss due to illness are left in the dark about potentially life-changing treatments—despite widespread state-level support and growing scientific evidence. That's the stark reality we've faced for decades with medical marijuana and CBD. But here's the kicker: a groundbreaking shift is underway to change that, and it's sparking heated debates every step of the way.
Under the authority granted to me as President by the Constitution and the laws of the United States, this executive order is issued to accelerate progress in medical marijuana and cannabidiol research.
Section 1 dives into the heart of the matter: Purpose and Policy. Every American deserves top-tier access to medical treatments and cutting-edge research facilities. Back in 2023, the Food and Drug Administration (FDA) wrapped up an extensive review of marijuana's medical applications. What they discovered? Solid scientific backing for its effectiveness in treating anorexia tied to medical conditions, nausea and vomiting—think the debilitating side effects of chemotherapy—and various forms of pain. Chronic pain, for instance, plagues nearly one out of every four adults in the U.S., and over one-third of seniors. Shockingly, six out of ten people who turn to medical marijuana do so specifically to manage pain. Forty states plus the District of Columbia have rolled out their own regulated medical marijuana programs at the state or local level. Yet, federal drug policies have dragged their feet for years, ignoring marijuana's therapeutic potential. This neglect has stifled scientists and manufacturers from conducting the vital research needed to ensure safety and effectiveness, leaving doctors and patients without reliable data.
Currently, marijuana sits under Schedule I of the Controlled Substances Act (CSA), a classification that paints it as a drug with no accepted medical use, high abuse potential, and no safe medical supervision. But in 2023, the Department of Health and Human Services (HHS) advised the Drug Enforcement Agency to bump it down to Schedule III. Schedule III substances are seen as having less abuse potential than those in Schedules I and II, with a recognized medical role in treatment here in the States, and a moderate to low risk of physical dependence or high psychological dependence if misused.
This HHS recommendation hinged on marijuana's established medical value, backed by data from the HHS Office of the Assistant Secretary of Health. They found that over 30,000 licensed healthcare providers across 43 U.S. jurisdictions are empowered to prescribe it for more than 6 million registered patients, targeting at least 15 different medical conditions. The FDA added credence with evidence supporting marijuana for pain relief, anorexia linked to certain illnesses, and chemotherapy-induced nausea and vomiting. Even the National Institute on Drug Abuse (NIDA) agreed with the FDA's push to reschedule from Schedule I to Schedule III. Fast-forward to May 2024, when the Department of Justice unveiled a proposed rule to make this change. It drew nearly 43,000 public comments and is now pending an administrative law hearing.
Now, here's where it gets controversial: The federal government's prolonged hesitation in acknowledging marijuana's medical benefits isn't just an oversight—it's harming countless Americans who swear by its relief for chronic pain and other approved conditions. Take those seeking alternatives to traditional pain management; they're hit hardest. For example, a research survey revealed that 20% of U.S. veterans participating reported cutting back on opioids thanks to medical marijuana. Among seniors, one in ten used it last year, with studies showing boosts in their overall health quality and pain levels. But—and this is the part most people miss—the Schedule I label has thrown up roadblocks for research. Without thorough studies and FDA approval, patients and doctors fly blind on how to prescribe or use it safely. A patient survey indicated that only 56% of older Americans using marijuana had chatted about it with their healthcare provider. This risky gap is especially concerning for seniors juggling multiple meds, heightening chances of dangerous interactions or side effects. Clearly, the federal government needs to ramp up research infrastructure for medical marijuana to truly serve Americans.
Expanding the conversation to cannabidiol (CBD), which often comes into play alongside medical marijuana—comprising primarily two cannabinoids, CBD and THC—let's explore hemp-derived products. Defined in section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o), these have shown promise in easing symptoms of everyday ailments and are increasingly popular among Americans. One in five adults and nearly 15% of seniors reported CBD use in the past year, with chronic pain sufferers noting improvements in clinical trials. Intriguingly, the THC content in these hemp products can influence both how well they treat pain and any unwanted side effects. Hemp-derived cannabinoids aren't classified as controlled substances under the CSA, but they fall under FDA regulations like any other product. Complicating matters, some full-spectrum CBD items will revert to marijuana status under the CSA once section 781 of Public Law 119-37 takes effect, due to THC levels exceeding per-container limits. To top it off, a recent study uncovered that many commercial CBD products are mislabeled—claiming to be CBD isolate, broad-spectrum, or full-spectrum when they're not—raising safety concerns for consumers. In essence, the current laws leave patients and doctors navigating a maze without clear guidance or protections for CBD.
This administration's stance? We're committed to bolstering research on medical marijuana and CBD to empower patients and physicians with better information. Bridging the divide between widespread use and scientific understanding of risks and benefits is crucial, especially for vulnerable groups like adolescents and young adults. Research approaches should incorporate real-world data and ensure accessible, affordable options to quickly evaluate health impacts of medical marijuana and legal CBD products, with a spotlight on long-term effects.
Section 2 outlines action: Rescheduling Medical Marijuana and Improving Access to Cannabidiol Products. (a) The Attorney General must expedite the rulemaking to reschedule marijuana to Schedule III under the CSA, adhering to federal laws like 21 U.S.C. 811.
(b) The Assistant to the President and Deputy Chief of Staff for Legislative, Political, and Public Affairs will collaborate with Congress to refine the definition of hemp-derived cannabinoid products. This aims to give Americans safe access to full-spectrum CBD while upholding congressional goals to curb risky products. They'll consult with relevant departments and agencies to craft a regulatory framework, including guidelines on THC limits per serving, container caps, and CBD-to-THC ratios. Meanwhile, the Secretary of Health and Human Services, the FDA Commissioner, the Centers for Medicare and Medicaid Services Administrator, and the National Institutes of Health Director will pioneer research techniques using real-world evidence to enhance access to hemp products and shape care standards, all within legal bounds.
Section 3 covers General Provisions. (a) Nothing here undermines:
(i) the legal powers of any executive department or agency, or its leader; or
(ii) the Office of Management and Budget Director's role in budget, administrative, or legislative matters.
(b) Implementation aligns with existing laws and available funds.
(c) This order doesn't create enforceable rights or benefits for anyone against the U.S., its entities, officers, or others.
(d) Publication costs are covered by the Department of Health and Human Services.
DONALD J. TRUMP
THE WHITE HOUSE,
December 18, 2025.
So, what do you think? Is rescheduling marijuana long overdue, or does it open the door to too many unknowns? Do you believe CBD products should be more regulated to prevent mislabeling, or is the current system flexible enough? Share your thoughts in the comments—let's debate the future of these therapies!
